Pharma and Biotechs developing ion channel therapeutics

The majority of big pharma companies as well as many biotech companies show their interest in ion channel targets. Here they are.

Company NameWebsiteInfoCountry
Abilita Biohttp://www.abilitabio.com/Membrane protein drug discovery. Development of Nav1.7 and Nav1.8 modulators for pain management.USA
Ablynxhttps://www.ablynx.com/Development of nanobodies. Their website states that multiple programmes are on-going, both internally and with partners.Belgium
Acesion Pharmahttp://www.acesionpharma.comDevelopment of SK channel inhibitors for the treatment of atrial fibrillation.Denmark
Algiax Pharmaceuticals
http://www.algiax.com/
Development of GABA-A modulators for the treatment of neuropathic pain and diabetes.
Germany
Alion Pharmaceuticalshttps://www.alion-pharmaceuticals.comDevelops small molecules targeting ion channels to treat CNS diseases.USA
Amgenhttps://www.amgen.com/Development of Nav1.7 modulators for pain management.USA
Asana BioSciences
https://www.asanabiosciences.com/

Develoment of ASN008, a topical sodium channel blocker, for the treatment of pruritus, atopic dermatitis and pain. ASN009, a P2X3 antagonist, for the treatment of cough, pruritus and pain.
USA
Autifony Therapeuticshttps://autifony.comModulators of Kv3.1 and Kv3.2 channels to treat disorders of the central nervous system.United Kingdom
BELLUS Health
https://bellushealth.com/
Development of BLU-5937, a highly selective P2X3 antagonist, for the treatment of chronic cough and chronic pruritus.
Canada
Biogenhttps://www.biogen.comDevelopment of Nav1.7 blockers for the treatment of neuropathic pain (BIIB074 -vixotrigine and BIIB095).USA
Bionomicshttps://www.bionomics.com.auBNC210 - negative modulator of an alpha7 nicotinic acetylcholine receptor for the treatment of anxiety disorders.Australia
Biosceptrehttp://www.biosceptre.com/Development of cancer therapeutics targeting nfP2X7.United Kingdom
Cadent Therapeuticshttp://www.cadenttx.comModulators of SK channels and NMDA receptors to treat movement and cognitive disorders.USA
Calchanhttp://www.calchan.co.ukCNV2197944 small molecule blocker of Cav2.2 for management of chronic pain.United Kingdom
CalciMedica
https://www.calcimedica.com/
Development of CRAC channel inhibitors for the treatment of acute and chronic inflammatory diseases.USA
Caraway Therapeutics
https://carawaytx.com/
Development of TRPML1 modulators for the treatment of neurodegenerative disorders.
USA
Casma Therapeutics
https://www.casmatx.com/
Development of TRPML1 agonist for the treatment of muscular dystrophy.
USA
Cavionhttp://cavionpharma.comDevelopment of T-type calcium channel modulators for movement disorders and rare, pediatric epilepsies.USA
Celex Oncologyhttp://celex-oncology.comDevelopment of voltage-gated sodium channel modulators for treating aggressive, invasive and metastatic cancer forms.UK
CerSci Therapeutics
https://cersci.com/
Development of CT-044, a powerful reactive species decomposition accelerant, preventing hyper-activation of TRPA1 to treat acute post-operative and chronic neuropathic pain.
USA
Cerevel Therapeutics
https://www.cerevel.com/
Development of CVL-865, a novel α2/3/5-subtype selective GABAA receptor positive allosteric modulator, for the treatment of epilepsy.
USA
Channel Biologics
Generation of biologics against difficult targets such as ion channels and GPCRs for the treatment of a variety of diseases.
Australia
CODA Biotherapeuticshttps://www.codabiotherapeutics.com/Imploys gene therapy approach to express tunable ligand-gated ion channels in neurons for the treatment of neurological diseasesUSA
CyThera Pharmaceuticals
https://www.cytherapharm.com/
Development of Kv1.3 inhibitor for the treatment of autoimmune diseases.
USA
Daewoong Pharmaceutical
https://www.daewoong.com
Development of ion channel-targeting molecules for the treatment of noise-induced hearing loss. Non-opioid analgesics targeting Nav1.7.
South Korea
Engrail Therapeutics
https://engrail.com/
Development of ENX-101, a sub-type selective GABA A modulator for the treatment of diseases of the nervous system.
USA
Enterprise Therapeuticshttp://enterprisetherapeutics.comTMEM16A potentiator and ENaC blocker for the treatment of respiratory diseases.United Kingdom
Flexion Therapeutics
https://flexiontherapeutics.com/
Development of FX301 (funapide), a locally administered NaV1.7 inhibitor for control of post-operative pain.
USA
Genentechhttps://www.gene.com/Development of TRPA1 modulatorsUSA
Glenmark Pharmaceuticalshttp://www.glenmarkpharma.comGRC 17536, a TRPA1 antagonist, to treat neuropathic pain.India
Goldfinch Bio
https://www.goldfinchbio.com/
Develompent of GFB-887, a sub-type selective, small molecule TRPC5 ion channel inhibitor for the treatment of kidney diseases.
USA
Idorsia Pharmaceuticalshttps://www.idorsia.comDevelopment of ACT-709478 - T-type calcium channel blocker for the treatment of epilepsy.Switzerland
Imbrium Therapeuticshttp://www.imbriumthera.comA subsidiary of Purdue Pharma. Collaboration with TetraGenetics on the discovery and development of non-opioid biologic therapies (monoclonal antibodies) for the treatment of chronic pain. Undisclosed ion channel targets.USA
ImmunoPrecisehttp://modiquestresearch.nl/In collaboration with TetraGenetics the company is developing human monoclonal antibodies against three undisclosed therapeutically-relevant ion-channels.The Netherlands
iN Therapeutics
A spinoff of Daewoong Pharmaceutical. Development of non-opioid analgesics targeting Nav1.7.
South Korea
Integral Molecularhttps://www.integralmolecular.com/Preclinical monoclonal antibody discovery programs. Development of MABs against Kv1.3 and P2X7 (immune modulation), P2X3 and Nav1.7 (pain). USA
Ionis Pharmaceuticals
https://www.ionispharma.com/
Development of RNA-targeted therapeutics. Developent of the ENaC antisense oligonucleotides for the treatment of cystic fibrosis. Co-development of PRAX-222/RC-222, SCN2A antisense oligonucleotide, together with Ionis and RogCon.
USA
IONTAS
https://www.iontas.co.uk/
Development of innovative antibody technologies facilitating targeting of ion channels. KnotBody® Technology. Active programs on Kv1.3, NaV1.7 & ASIC1a.
United Kingdom
Kinetahttps://www.kinetabio.comalpha9alpha10 nAChR antagonists for the treatment of chronic pain.USA
Knopp Bioscienceshttps://knoppbio.com/Development of Kv7 modulators for the treatmnet of epileptic encelophaty, neuropathic pain, hearing disorders and ALSUSA
Lillyhttps://www.lilly.comTRPA1 antagonist for pain management (preclinical TRPA1 program acquired from Hydra Biosciences in 2018).USA
Merckhttps://www.merck.com/Development of TRPML1 agonists for the treatment of neurodegenerative disorders; Gefapixant, selective P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough.
Germany
Neurocrine Biosciences
https://www.neurocrine.com/
Development of Nav1.6 inhibitors and dual Nav1.2/1.6 inhibitors, for the treatment of neurological disorders. Partnership with Xenon.
USA
NMD Pharma
http://www.nmdpharma.com/
Development of ClC-1 chloride channel blockers for the treatment of neuromuscular disorders
Denmark
Nocion Therapeuticshttps://www.nociontx.comDevelopment of small molecules called nocions, which are sodium channel blockers, for the treatment of serious conditions including cough, itch, pain, and inflammation.USA
Novassayhttp://www.novassay.comIon channel drug development programs in Neuropathic Pain and Oncology. CACNA2D1 subunit.Switzerland
Ono Pharma
https://www.ono.co.jp/eng/
Interested in the development of novel modulators of potassium channels
Japan
Pano Therapeutics
Development of mitochondrial ion channel modulators for the treatment of cancer and cardiometabolic syndromes.
USA
Parion Scienceshttp://www.parion.comENaC inhibitors for the treatment of pulmonary diseases (in partnership with Vertex) and dry eye disease. Small molecule CFTR correctors for the treatment of cystic fibrosis.USA
PILA PHARMAhttp://pilapharma.com/PILA PHARMA is developing a TRPV1 antagonist, XEN-D0501, for the treatment of diabetes.Sweden
Praxis
https://praxismedicines.com/
Development of PRAX-114, a GABAA positive allosteric modulator for the treatment of major depressive disorder and perimenopausal depression, and PRAX-944, a T-type calcium channel blocker for the treatment of essential tremor.
USA
QUE Oncologyhttps://www.queoncology.com/Apparently, the development of drugs and antibodies targeting the ORAI1 channel in breast cancer.USA-Australia
QurAlishttps://quralis.com/Development of Kv7.2/7.3 modulators for the treatment of amyotrophic lateral sclerosis.USA
Redpin Therapeutics
https://www.redpinrx.com/
Development of an ultrapotent ion channel-based chemogenetics platform that enables targeted cell activation or inhibition controlled by low doses of the anti-smoking drug varenicline (CHANTIX®).
USA
Regulonixhttps://regulonix.comDeveloping non-opioid therapeutics that relieve chronic pain. NaV1.7.USA
Rhizen Pharmaceuticals
http://www.rhizen.com/
Development of CRAC channel inhibitor RP4010 for cancer treatment.
Switzerland
RogCon Biosciences
https://www.rogcon.com/
Discovery and development of novel therapeutics for children suffering from SCN2A mutations.
USA
RogCon U.R.
https://www.rogcon.com/
RogCon U.R., a sister company of RogCon Biosciences, is focused on the research and development of novel, disease-modifying compounds that up-regulate SCN2A for the treatment of loss-of-function mutations in SCN2A causing autism and epilepsy.
USA
Salipro Biotech
https://www.salipro.com/
Development of drugs targeting membrane proteins using its proprietary nano-membrane technology. Undisclosed ion channel target.
Sweden
Sanionahttps://saniona.comSAN711 (a selective GABAA alpha3 modulator) for treatment of chronic itching and neuropathic pain.
CAD-1883 (a first-in-class selective positive allosteric modulator of SK channels) for the treatment of essential tremor and spinocerebellar ataxia.
Development of modulators of nicotinic acetylcholine (nAChRs) receptors for therapy against Parkinson's disease.
Development of IK potassium channel (KCa3.1) modulator medicine for inflammatory bowel diseases.
Kv7 programs for the treatment of epilepsy, pain, and urinary incontinence.
Denmark
selectIONhttp://selectiontherapeutics.comsi-544 - Kv1.3 blocker for treatment of effector memory T cell driven diseases.USA
Shionogi
https://www.shionogi.com/
Development of a P2X3 antagonist, S-600918, for the treatment of refractory chronic cough
Japan, USA
SiteOne Therapeuticshttps://www.siteonetherapeutics.comSmall molecule inhibitors of Nav 1.7 sodium channel to treat acute and chronic pain.USA
Soricimed Biopharmahttps://www.soricimed.comSOR-C13 peptide inhibiting TRPV6 for cancer treatment.Canada
Stoke Therapeutics
https://www.stoketherapeutics.com/
Development of STK-001 anti-sense oligonucleotide medicine increasing healthy copies of the Nav1.1 (SCN1A) sodium channel for the treatment of Dravet syndrome.
USA
TetraGeneticshttp://www.tetragenetics.comDiscovery and development of novel ion channel therapeutics for autoimmune diseases and pain using proprietary technology TetraExpressUSA
Tevahttps://www.tevapharm.com/Ion channel antibody discovery programs.Israel, USA
Theranyxhttps://www.theranyx.com/Development of TherabodiesTM that act on several ion channels involved in pain and cancer.France
Vast Bioscience
http://www.vastbioscience.com/
Developing non-opioid pain therapeutics targeting Nav1.7 and Nav1.8.
Australia
Vertex Pharmaceuticalshttps://www.vrtx.com/Developing medicines targeting CFTR for the treatment of cystic fibrosis. ENaC inhibitors for the treatment of pulmonary diseases (in partnership with Parion Sciences). NaV 1.8 inhibitors for the treatment of pain.USA
VistaGen Therapeutics
https://www.vistagen.com/
Developing medications for anxiety, depression and other CNS diseases. NMDAR antagonist for the treatment of various CNS disorders.
USA
Xenon Pharmaceuticalshttps://www.xenon-pharma.comDevelopment of ion channel modulators for the treatment of neurological diseases.Canada
YourChoice Therapeutics
https://www.yourchoicetx.com/
Developing hormone-free contraceptives preventing CatSper activation.
USA